Deprenyl monotherapy improves visuo-motor control in early parkinsonism

Journal of Neural Transmission, Supplement

Volumn , Issue 52, 1998, Pages 63-69

  Hocherman, S ^a   Levin, G ^a   Giladi, N ^a   Youdim, M B H ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; METHAMPHETAMINE; SELEGILINE; ANTIPARKINSON AGENT;

ARTICLE; CLINICAL ARTICLE; DOPAMINE RELEASE; DOSE RESPONSE; EARLY DIAGNOSIS; HUMAN; PARKINSONISM; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; VISUOMOTOR COORDINATION; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HOSPITALIZATION; MALE; MOTOR ACTIVITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOMOTOR PERFORMANCE;

ANTIPARKINSON AGENTS; FEMALE; HUMANS; MALE; MOTOR ACTIVITY; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; SELEGILINE; SEVERITY OF ILLNESS INDEX;

EID: 0031596688     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6499-0_7     Document Type: Article

References (20)

1. Carrillo MC, Kitani K, Kanai S, Sato Y, Ivy GO (1992) The ability of (-)deprenyl to increase superoxide dismutase activities in the rat is tissue and brain region selective. Life Sci 50: 1985-1992
2. Chia LG, Liu SP, Lee EH (1992) Differential effects of deprenyl and MPTP on catecholamines and activity in BALB/c mice. Neuroreport 3: 777-780
3. Hocherman S, Aharon-Peretz J (1994) Two dimensional tracing and tracking in patients with Parkinson's disease. Neurol 44: 111-116
4. Hocherman S, Giladi N (1995) Early diagnosis of Parkinson's disease in new neurological patients by testing of Visuo -Manual coordination. In: Ohye C, Kimura M, McKenzie SJ (eds) The basal ganglia V. Plenum, New York, pp 427-431
5. Hubble JP, Koller WC, Waters C (1993) Effects of selegiline dosing on motor fluctuations in Parkinson's disease. Clin Neuropharmacol 16: 83-87
6. Jenkins IH, Fernandez W, Playford ED, Lees AJ, Frackowiak RSJ, Passingham RE, Phil D, Brooks DJ (1992) Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 32: 749-757
7. Knoll J (1992) (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system. J Am Geriatr Soc 40: 839-847
8. Knoll J, Toth V, Kummert M, Sugar J (1992) (-)Deprenyl and (-)parafluorodeprenyl-treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin. Mech Ageing Dev 63: 157-163
9. Okuda C, Segal DS, Kuczenski R (1992) Deprenyl alters behavior and caudate dopamine through an amphetamine-like action. Pharmacol Biochem Behav 43: 1075-1080
10. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 3: 176-183
11. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 39: 37-45
12. Shoulson I (1992) An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group. Eur Neurol 32: 46-53
13. Shults CW (1993) Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group. Acta Neurol Scand [Suppl] 146: 36-42
14. Schulzer M, Mak E, Calne DB (1992) The antiparkinson efficacy of Deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 32: 795-798
15. Tardos L, Janvarine Kanyo E (1992) Pharmacology of selegiline (recent considerations). Acta Pharm Hung 62: 237-241
16. Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action of deprenyl in MPTP parkinsonism. J Neurosci Res 30: 666-672
17. Vezina P, Mohr E, Grimes D (1992) Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects. Can J Neurol Sci 19: 142-146
18. Vrana SL, Azzaro AJ, Vrana KE (1992) Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway. Mol Pharmacol 41: 839-844
19. Yasar S, Schindler CW, Thorndike EB, Szelenyi I, Goldberg SR (1993) Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats. J Pharmacol Exp Ther 265: 1-6
20. Ziv I, Achiron A, Djaldetti R, Dressier R, Melamed E (1993) Short-term beneficial effect of deprenyl monotherapy in early Parkinson's disease: a quantitative assessment. Clin Neuropharmacol 16: 54-60